These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 28271038)

  • 1. Successful crizotinib monotherapy in
    Yoshimura K; Inui N; Karayama M; Inoue Y; Enomoto N; Fujisawa T; Nakamura Y; Takeuchi K; Sugimura H; Suda T
    Respir Med Case Rep; 2017; 20():160-163. PubMed ID: 28271038
    [No Abstract]   [Full Text] [Related]  

  • 2. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
    Wang W; Wang H; Lu P; Yu Z; Xu C; Zhuang W; Song Z
    J Transl Med; 2019 Feb; 17(1):52. PubMed ID: 30791921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification.
    Furugaki K; Fukumura J; Iwai T; Yorozu K; Kurasawa M; Yanagisawa M; Moriya Y; Yamamoto K; Suda K; Mizuuchi H; Mitsudomi T; Harada N
    Int J Cancer; 2016 Feb; 138(4):1024-32. PubMed ID: 26370161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.
    Costa DB; Nguyen KS; Cho BC; Sequist LV; Jackman DM; Riely GJ; Yeap BY; Halmos B; Kim JH; Jänne PA; Huberman MS; Pao W; Tenen DG; Kobayashi S
    Clin Cancer Res; 2008 Nov; 14(21):7060-7. PubMed ID: 18981003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential response to a combination of full-dose osimertinib and crizotinib in a patient with
    Zhu VW; Schrock AB; Ali SM; Ou SI
    Lung Cancer (Auckl); 2019; 10():21-26. PubMed ID: 30881166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP).
    Cardona AF; Arrieta O; Zapata MI; Rojas L; Wills B; Reguart N; Karachaliou N; Carranza H; Vargas C; Otero J; Archila P; Martín C; Corrales L; Cuello M; Ortiz C; Pino LE; Rosell R; Zatarain-Barrón ZL;
    Target Oncol; 2017 Aug; 12(4):513-523. PubMed ID: 28620690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report.
    Blasi M; Kazdal D; Thomas M; Christopoulos P; Kriegsmann M; Brandt R; Volckmar AL; Kirchner M; Heußel CP; Stenzinger A; Kuon J
    Case Rep Oncol; 2021; 14(1):477-482. PubMed ID: 33976623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case Report: Durable partial response to icotinib plus crizotinib in a lung adenocarcinoma patient with double uncommon
    Ou L; Tang Y; Deng Y; Guo L; He Q; He T; Feng W
    Front Oncol; 2022; 12():911362. PubMed ID: 35957915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.
    Yano S; Yamada T; Takeuchi S; Tachibana K; Minami Y; Yatabe Y; Mitsudomi T; Tanaka H; Kimura T; Kudoh S; Nokihara H; Ohe Y; Yokota J; Uramoto H; Yasumoto K; Kiura K; Higashiyama M; Oda M; Saito H; Yoshida J; Kondoh K; Noguchi M
    J Thorac Oncol; 2011 Dec; 6(12):2011-7. PubMed ID: 22052230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation tracking of a patient with EGFR-mutant lung cancer harboring de novo MET amplification: Successful treatment with gefitinib and crizotinib.
    Zheng X; Zhang G; Li P; Zhang M; Yan X; Zhang X; Yang J; Li H; Liu X; Ma Z; Wang H
    Lung Cancer; 2019 Mar; 129():72-74. PubMed ID: 30797494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance.
    Liu L; Qu J; Heng J; Zhou C; Xiong Y; Yang H; Jiang W; Zeng L; Zhu S; Zhang Y; Tan J; Hu C; Deng P; Yang N
    Front Oncol; 2021; 11():722039. PubMed ID: 34660287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.
    van Veggel B; de Langen AJ; Hashemi S; Monkhorst K; Rosenberg EH; Heideman DAM; Radonic T; Smit EF
    Lung Cancer; 2018 Oct; 124():130-134. PubMed ID: 30268451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.
    Rosell R; Dafni U; Felip E; Curioni-Fontecedro A; Gautschi O; Peters S; Massutí B; Palmero R; Aix SP; Carcereny E; Früh M; Pless M; Popat S; Kotsakis A; Cuffe S; Bidoli P; Favaretto A; Froesch P; Reguart N; Puente J; Coate L; Barlesi F; Rauch D; Thomas M; Camps C; Gómez-Codina J; Majem M; Porta R; Shah R; Hanrahan E; Kammler R; Ruepp B; Rabaglio M; Kassapian M; Karachaliou N; Tam R; Shames DS; Molina-Vila MA; Stahel RA;
    Lancet Respir Med; 2017 May; 5(5):435-444. PubMed ID: 28408243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
    Shea M; Costa DB; Rangachari D
    Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
    Okabe T; Okamoto I; Tsukioka S; Uchida J; Hatashita E; Yamada Y; Yoshida T; Nishio K; Fukuoka M; Jänne PA; Nakagawa K
    Clin Cancer Res; 2009 Feb; 15(3):907-13. PubMed ID: 19188161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
    Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM
    Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
    Matsumoto Y; Maemondo M; Ishii Y; Okudera K; Demura Y; Takamura K; Kobayashi K; Morikawa N; Gemma A; Ishimoto O; Usui K; Harada M; Miura S; Fujita Y; Sato I; Saijo Y;
    Lung Cancer; 2014 Nov; 86(2):195-200. PubMed ID: 25249428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.
    Yamada T; Matsumoto K; Wang W; Li Q; Nishioka Y; Sekido Y; Sone S; Yano S
    Clin Cancer Res; 2010 Jan; 16(1):174-83. PubMed ID: 20008840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
    Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
    Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report.
    Zhang Y; Chen HM; Liu YM; Peng F; Yu M; Wang WY; Xu H; Wang YS; Lu Y
    World J Clin Cases; 2019 May; 7(10):1221-1229. PubMed ID: 31183356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.